Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of “Moderate Buy” by Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $56.9091.

JANX has been the topic of several research reports. HC Wainwright cut their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. UBS Group reaffirmed a “buy” rating and set a $57.00 target price on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Stifel Nicolaus reduced their price target on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, December 2nd. Finally, Guggenheim decreased their price objective on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research note on Friday, February 27th.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $13.18 on Monday. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34. The firm’s 50-day moving average is $13.68 and its two-hundred day moving average is $19.26. The stock has a market cap of $801.74 million, a price-to-earnings ratio of -7.20 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.14. The business had revenue of $7.88 million during the quarter, compared to the consensus estimate of $0.08 million. On average, equities analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Zachariah Mciver sold 2,714 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $37,263.22. Following the completion of the sale, the insider directly owned 23,286 shares of the company’s stock, valued at approximately $319,716.78. This represents a 10.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Charles M. Winter sold 2,401 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $32,965.73. Following the completion of the sale, the insider owned 77,721 shares in the company, valued at $1,067,109.33. This represents a 3.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 19,033 shares of company stock valued at $261,323 in the last three months. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its stake in shares of Janux Therapeutics by 1.1% during the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after acquiring an additional 404 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Janux Therapeutics by 8.1% in the 2nd quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after purchasing an additional 771 shares during the last quarter. Nuveen LLC boosted its stake in Janux Therapeutics by 0.8% in the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after purchasing an additional 787 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Janux Therapeutics by 25.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after purchasing an additional 820 shares in the last quarter. Finally, Virtus Investment Advisers LLC grew its position in Janux Therapeutics by 37.9% during the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares during the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.